The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Combination strategies for lung cancer resistant to targeted therapies
Melina Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, explores potential treatment strategies for patients with lung cancer who progress on existing targeted therapies. MET inhibitors have shown promise, especially considering that MET alterations are common in patients who are resistant to EGFR and ALK tyrosine kinase inhibitors (TKIs). This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
